Article
Nanoscience & Nanotechnology
Parisa Badiee, Michelle F. Maritz, Nicole Dmochowska, Edward Cheah, Benjamin Thierry
Summary: This study investigates the biodistribution of intratumorally administered aPD-1 nanoformulation and finds that it has lower off-target organ distribution and higher accumulation in tumors and tumor draining lymph nodes compared to free antibodies. In vitro studies also show that aPD-1 nanoformulation effectively inhibits PD-1 expression on T-cells and enhances their cytotoxicity against head and neck cancer cells. Further research is needed to assess the potential of intratumoral administration of aPD-1 nanoformulation in reducing toxicity and improving the tumor efficacy of immune checkpoint inhibitors.
ACS APPLIED MATERIALS & INTERFACES
(2022)
Article
Multidisciplinary Sciences
Zhen Bian, Lei Shi, Koby Kidder, Ke Zen, Charlie Garnett-Benson, Yuan Liu
Summary: This study demonstrates that depleting SIRP alpha on intratumoral macrophages enhances the efficacy of radiotherapy to eliminate large, treatment-resistant colorectal and pancreatic tumors, inducing complete abscopal remission and long-lasting immune responses that prevent recurrence. This suggests that targeting SIRP alpha could serve as a promising strategy for treating a broad spectrum of cancers, including advanced stages with low immunogenicity and metastases.
NATURE COMMUNICATIONS
(2021)
Review
Chemistry, Analytical
Pei Wang, Longfei Tang, Bohui Zhou, Liangfen Cheng, Robert Chunhua Zhao, Juan Zhang
Summary: Immune checkpoints are a series of molecules that regulate the degree of immune activation, including PD-1/PD-L1, CTLA-4, LAG-3, and others. Immune checkpoint therapy is considered to be a safer and more effective treatment for tumor immunotherapy compared to conventional therapy. The analysis of immune checkpoints is crucial for immunotherapy medication, treatment, and prognosis evaluation.
TRAC-TRENDS IN ANALYTICAL CHEMISTRY
(2022)
Article
Oncology
Afshin Derakhshani, Shahryar Hashemzadeh, Zahra Asadzadeh, Mahdi Abdoli Shadbad, Farnaz Rasibonab, Hossein Safarpour, Vahid Jafarlou, Antonio Giovanni Solimando, Vito Racanelli, Pankaj Kumar Singh, Souzan Najafi, Darya Javadrashid, Oronzo Brunetti, Nicola Silvestris, Behzad Baradaran
Summary: The study revealed an increasing trend of CTLA-4 in colorectal cancer (CRC) and the inhibitory molecule can be suppressed by the chemotherapy drug capecitabine. Inhibiting CTLA-4 can reactivate immune cells against tumors, potentially enhancing treatment outcomes.
Article
Medicine, Research & Experimental
Youliang Zhao, Changfu Hao, Meng Li, Yaqian Qu, Yonghua Guo, Xuedan Deng, Huifang Si, Wu Yao
Summary: This study demonstrates the potential value of immune checkpoint inhibitors, particularly PD-1/PD-L1 inhibitors, in the treatment of silica-induced pulmonary fibrosis. The findings suggest that these inhibitors can modulate immune system disruption caused by silica exposure and provide new ideas for the treatment of fibrosis-related diseases.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Review
Biochemistry & Molecular Biology
Kai Hou, Xiaohui Xu, Xin Ge, Jiacen Jiang, Fan Ouyang
Summary: Immune checkpoints play a role in promoting tumor growth and inhibiting immune-mediated cancer cell apoptosis. Targeting immune checkpoints has been successful in treating various cancers, including hepatocellular carcinoma (HCC). However, some patients do not respond to this therapy due to acquired resistance and recurrence. Understanding the specific mechanisms of immune checkpoints in HCC development is crucial for improving the efficacy of anti-PD-1 and anti-CTLA-4 therapy.
Article
Chemistry, Multidisciplinary
Suchen Bian, Haijiang Dong, Long Zhao, Zequn Li, Jian Chen, Xingxin Zhu, Nasha Qiu, Xing Jia, Wenfeng Song, Zekuan Li, Shusen Zheng, Hangxiang Wang, Penghong Song
Summary: Losartan nanoblocker (Los NB) remodels the tumor microenvironment, enhances the accumulation and penetration of drugs in tumor tissues, and improves the therapeutic efficacy. This study provides a potential clinical transformation for stroma-rich PDAC treatment.
Review
Medicine, Research & Experimental
Parisa Shiri Aghbash, Narges Eslami, Ali Shamekh, Taher Entezari-Maleki, Hossein Bannazadeh Baghi
Summary: The COVID-19 pandemic, caused by the outbreak of SARS-CoV-2 in Wuhan in December 2019, highlights the significance of respiratory disorders, lymphopenia, cytokine cascades, and immune responses in disease severity. Investigation of inhibitory immune checkpoints could impact treatment strategies, with T-cells playing a key role in clearing viral infections and reducing symptoms. Lymphocyte depletion and enhanced expression of inhibitory immune checkpoints in individuals with COVID-19 contribute to T-cell dysfunction and exhaustion, particularly in severe cases.
Article
Biochemistry & Molecular Biology
Jun Liu, David C. Yang, Jun Zhang, Ssu-Wei Hsu, Robert H. Weiss, Ching-Hsien Chen
Summary: The study demonstrates that in a cisplatin-induced AKI model, the kidneys show pathological damage consistent with the immune response to cisplatin treatment. The research findings suggest an association between the immune microenvironment of injured kidneys and increased infiltration of CD4+ T cells and macrophages, along with decreased Treg cell populations. Furthermore, the study reveals that cisplatin exposure downregulates PD-L1 protein levels in renal cells, but orthotopic delivery of the PD-L1 gene can lead to lower levels of kidney injury markers in mice exposed to cisplatin.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Oncology
Shuang Huang, Gang Zheng, Kai Yang
Summary: This systematic review and meta-analysis evaluated the efficacy and safety of neoadjuvant PD-1/PD-L1 inhibitors combined with CTLA-4 inhibitors in malignant solid tumors. The results showed that the addition of CTLA-4 inhibitors did not significantly improve overall response rate and survival outcomes. However, there was an increased risk of grade 3-4 adverse events with the combination therapy. More large-scale and multicenter randomized controlled trials are needed to obtain more reliable results.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2023)
Review
Oncology
Allan Relecom, Maysaloun Merhi, Varghese Inchakalody, Shahab Uddin, Darawan Rinchai, Davide Bedognetti, Said Dermime
Summary: Immune checkpoint inhibitors have shown therapeutic benefits in solid cancers and some hematological malignancies, but predicting treatment response remains challenging. Studies on the dynamics of the immune system and tumor under immune checkpoint blockade have revealed mechanisms of action and adaptive resistance to these therapeutic agents.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2021)
Article
Biochemistry & Molecular Biology
Tomislav Ivanovic, Dorotea Bozic, Benjamin Benzon, Vesna Capkun, Katarina Vukojevic, Merica Glavina Durdov
Summary: Gastric cancer (GC) therapies include gastrectomy and chemoradiotherapy. The tumor immune microenvironment (TME) has implications for potential immunotherapy. We analyzed the expression of PD-L1, CD8, CTLA-4, and IFN-? in the tumor and regional lymph node (LN) of patients with GC and found correlations between PD-L1 expression and tumor type, CD8+ T cells, and macrophages, as well as between IFN-? expression and CTLA4(+) lymphocytes. Overall survival was negatively correlated with IFN-? expression in metastases. Rating: 8/10.
Article
Biochemistry & Molecular Biology
Amin Daei Sorkhabi, Aila Sarkesh, Ali Fotouhi, Hossein Saeedi, Leili Aghebati-Maleki
Summary: This study aimed to assess the effect of mono, dual, and triple combinations of CTLA-4, PD-L1, and TIM3 blockade on osteosarcoma cell viability, apoptosis, and migration. The results showed that triple blockade had the most significant impact on cell viability, apoptosis rate, and migration inhibition.
Article
Agriculture, Dairy & Animal Science
Ilaria Porcellato, Samanta Mecocci, Chiara Brachelente, Katia Cappelli, Federico Armando, Alessia Tognoloni, Elisabetta Chiaradia, Valentina Stefanetti, Luca Mechelli, Marco Pepe, Rodolfo Gialletti, Benedetta Passeri, Alessandro Ghelardi, Elisabetta Razzuoli
Summary: The study investigated the expression of PD-L1 and CTLA-4 in penile tumors of horses, particularly in malignant squamous cell carcinomas. Results showed that these molecules are not frequently expressed in equine penile tumors, suggesting limited efficacy of ICI in treating these tumors.
Review
Oncology
Liming Liao, Huilin Xu, Yuhan Zhao, Xiaofeng Zheng
Summary: Immunotherapies based on immune checkpoint blockade have improved cancer therapy outcomes in the past decade. However, some patients show poor responsiveness to this therapy, and the underlying mechanism is not well understood. Recent studies have shown that targeting tumor metabolism in combination with immune checkpoint inhibitors provides new approaches to cancer therapy.
FRONTIERS OF MEDICINE
(2023)
Meeting Abstract
Oncology
Ian B. Walters, Lewis H. Bender, Masaki Terabe, Jay A. Berzofsky
Meeting Abstract
Oncology
Ian B. Walters, Anja C. Bloom, Lewis H. Bender, Masaki Terabe, Jay A. Berzofsky
Meeting Abstract
Oncology
Yada Kanjanapan, Nilofer Saba Azad, Lillian L. Siu, Anthony J. Olszanski, Ian B. Walters, Lisa Kamen, Lewis H. Bender, Anthony B. El-Khoueiry
JOURNAL OF CLINICAL ONCOLOGY
(2018)
Meeting Abstract
Oncology
Anthony B. El-Khoueiry, Jacob Stephen Thomas, Diana L. Hanna, Lillian L. Siu, Nilofer Saba Azad, Giles Francis Whalen, Lewis H. Bender, Ian B. Walters, Anthony J. Olszanski
JOURNAL OF CLINICAL ONCOLOGY
(2019)
Article
Oncology
Anja C. Bloom, Lewis H. Bender, Shweta Tiwary, Lise Pasquet, Katharine Clark, Tianbo Jiang, Zheng Xia, Aizea Morales-Kastresana, Jennifer C. Jones, Ian Walters, Masaki Terabe, Jay A. Berzofsky
Meeting Abstract
Oncology
Anja C. Bloom, Lewis H. Bender, Ian B. Walters, Katharine T. Clark, Masaki Terabe, Jay A. Berzofsky
Meeting Abstract
Hematology
Shaker A. Mousa, Haifeng Zhang, Ahmad Aljada, Fuming Zhang, Ehud Arbit, Lewis Bender, Michael Goldberg, Robert Linhardt